Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts


DOP85: Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapyECCO'22
Year: 2022
Authors: Baert, F.J.(1);Atreya, R.(2);Kakuta, Y.(3);Long, M.(4);Roblin, X.(5);Neimark, E.(6);Song, A.(6);Wallace, K.(6);Kingys, K.(6);Mallick, M.(6);Liao, X.(6);Lim, A.(7);
(1)AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium;(2)Friedrich-Alexander-University Erlangen-Nürnberg- University Hospital Erlangen, Department of Medicine, Erlangen, Germany;(3)Tohoku University Graduate School of Medicine, Division of Gastroenterology, Seiryo- Aoba- Sendai, Japan;(4)University of North Carolina, Division of Gastroenterology and Hepatology- Multidisciplinary Center for Inflammatory Bowel Diseases, Chapel Hill, United States;(5)University Hospital of Saint-Étienne, Department of Gastroenterology, Saint-Étienne, France;(6)AbbVie Inc., Department of Gastroenterology, North Chicago, United States;(7)John Flynn Private Hospital, Department of Gastroenterology, Tugun- Queensland, Australia;
DOP86: Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active Ulcerative ColitisECCO'22
Year: 2022
Authors: Steere, B.(1);Powell, N.(2);Higgs, R.(1);Wang, Y.C.(1);Milch, C.(1);Sandborn, W.J.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Krishnan, G.(1);
(1)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(2)Imperial College London, Gastroenterology, London, United Kingdom;(3)University of California San Diego, Gastroenterology, San Diego, United States;(4)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(5)Medical University of Vienna, Internal Medicine, Vienna, Austria;(6)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;
DOP87: Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s DiseaseECCO'22
Year: 2022
Authors: Magro, F.(1);De Hertogh, G.(2);Protic, M.(3);Chan, L.S.(3);Pollack, P.(3);Feagan, B.G.(4);Harpaz, N.(5);Pai, R.(6);Reinisch, W.(7);
(1)University Hospital São João, Pharmacology, Porto, Portugal;(2)KU Leuven, University Hospitals Leuven, Leuven, Belgium;(3)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(4)Robarts Clinical Trials Inc, Medicine- Epidemiology & Biostatistics, London, Canada;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(6)The Mayo Clinic, Gastroenterology, Scottsdale, United States;(7)Medical University of Vienna, Internal Medicine, Vienna, Austria;
DOP88: Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTEECCO'22
Year: 2022
Authors: Bello, F.(1);Lördal, M.(2);Johansson, F.(3);Sabhan, H.(4);Muhsen, S.(2);Borin, A.(5);Forsberg, O.(6);Wennerström, C.(6);Söderman, C.(4);Almer, S.(1);
(1)Karolinska University Hospital, IBD-Unit- Division of Gastroenterology, Stockholm, Sweden;(2)Danderyd Hospital, Divsion of Gastroenterology and Hepatology- Department of Medicine, Danderyd, Sweden;(3)Danderyd Hospital, Medical Library, Danderyd, Sweden;(4)S:t Göran’s Hospital, Gastroenterology Unit- Medical Department, Stockholm, Sweden;(5)South Hospital, Department of Medicine, Stockholm, Sweden;(6)Janssen Cilag AB, Immunology, Stockholm, Sweden;
DOP89: Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s DiseaseECCO'22
Year: 2022
Authors: Wang, Z.(1);Kantasiripitak, W.(1);Verstockt, B.(2,3);João, S.(2,3);Ferrante, M.(2,3);Declerck, P.(1);D’Haens, G.(4);Laharie, D.(5);Vermeire, S.(2,3);Dreesen, E.(1);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Université de Bordeaux, Department of Hepato-gastroenterology and Digestive Oncology, Bordeaux, France;
DOP90: Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trialECCO'22
Year: 2022
Authors: Peyrin-Biroulet, L.(1);Vermeire, S.(2);D'Haens, G.R.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Le Bars, M.(8);Lahaye , M.(9);Nazar, M.(10);Ni, L.(11);Bravatà , I.(12);Lavie , F.(9);Daperno , M.(13);Lukáš , M.(14);Armuzzi , A.(15);Löwenberg , M.(3);Gaya , D.R.(16);Danese , S.(17); STARDUST
(1)University Hospital of Nancy- University of Lorraine- INSERM U1256 NGERE, Department of Hepato-Gastroenterology, Houdemont, France;(2)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(3)Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands;(4)Hospital Clinic of Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(5)Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany;(6)Institute for Molecular and Cell Biology- Faculty of Medicine University of Porto, Department of Pharmacology & Therapeutics, Porto, Portugal;(7)Hospital de São João, Department of Gastroenterology, Porto, Portugal;(8)Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France;(9)Janssen-Cilag BV, Medical Affairs, Breda, The Netherlands;(10)Janssen-Cilag Polska Sp. z o.o, Medical Affairs, Warsaw, Poland;(11)Janssen-Cilag Russia, Medical Affairs, Moscow, Russian Federation;(12)Janssen-Cilag, Medical Affairs, Milan, Italy;(13)Mauriziano Hospital, Gastroenterology Unit, Turin, Italy;(14)Clinical Center ISCARE, Clinical and Research Center for Inflammatory Bowel Diseases, Prague, Czech Republic;(15)Fondazione Policlinico Universitario A. Gemelli IRCCS, IBD Unit- Università Cattolica del Sacro Cuore, Rome, Italy;(16)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(17)Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy;
N01: Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: a multicentre, comparative study.ECCO'22
Year: 2022
Authors: De Dycker, E.(1);Hoefkens, E.(2);Asnong, K.(2);Geens, P.(1);Lembrechts, N.(2);Lambrechts, T.(1);Van de Schoot, I.(2);Paps, A.(2);Vermeire, S.(1);Pouillon, L.(2);Ferrante, M.(1);Bossuyt, P.(2);
(1)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Imelda General Hospital Bonheiden, Department of Gastroenterology, Bonheiden, Belgium;
N02: The importance of the multidisciplinary team (MDT) and its impact on quality of life and medication adherence in patients with Inflammatory Bowel DiseaseECCO'22
Year: 2022
Authors: Herrerias, G.(1);Barros, J.R.(2);Lopes, M.A.(1);Saad-Hossne, R.(3);Baima, J.P.(4);Sassaki, L.Y.(4);
(1)São Paulo State University Unesp- Medical School- Botucatu, medical clinic department, Botucatu, Brazil;(2)Federal University of Rio de Janeiro- Macae- Brazil, Nursing Institute, Macaé/RJ, Brazil;(3)São Paulo State University Unesp- Medical School- Botucatu/SP, Department of surgery and orthopedics, Botucatu/SP, Brazil;(4)São Paulo State University Unesp- Medical School- Botucatu/SP, Department of Clinical Medicine, Botucatu/SP, Brazil;
N03: Medication adherence in relation to Health-related Quality of Life in patients with Inflammatory Bowel Disease – a cross-sectional studyECCO'22
Year: 2022
Authors: Johansson, E.(1);Lovén WickmanRN- PhD, U.(2);
(1)Linköping university, Medical student- Department of Medical and Health Sciences, Linköping, Sweden;(2)Linnaeus University, Department of Health and Caring Sciences, Kalmar, Sweden;
N04: A systematic review of the impact of Inflammatory Bowel Disease (IBD) on family membersECCO'22
Year: 2022
Authors: Thapwong, P.(1);Norton, C.(1);Rowland, E.(1);Farah, N.(1); Czuber- Dochan, W.(1);
(1)King's college London, Nursing faculty, London, United Kingdom;
N05: Patient involvement in inflammatory bowel disease therapy and disease-related parameters - is there an association?ECCO'22
Year: 2022
Authors: Haj Natour, O.(1);Magnezi, R.(2);Ben Horin, S.(3);Lipkin, M.(3);Ungar, B.(3);Galper, A.(3);Sina, S.(3);Kopylov, U.(3);
(1)Tel-HaShomer Sheba Medical Center+ Bar Ilan University, Department of Gastroenterology, Ramat Gan, Israel;(2)Bar Ilan University, Department of Manegment, Ramat Gan, Israel;(3)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
N06: Assessing stakeholder identified barriers and enablers to Ultrasound implementation for assessment of Crohn's Disease in the UK: A qualitative interview studyECCO'22
Year: 2022
Authors: RadfordBSc- MSc- PGCert- PhD student, S.(1);Leighton, P.(2);Coad, J.(3);Moran, G.(1);
(1)Nottingham NIHR Biomedical Research Centre, Liver and Gastrointestinal Disorders Translational Medicine, Nottingham, United Kingdom;(2)The University of Nottingham, Faculty of Medicine, Nottingham, United Kingdom;(3)University of Nottingham, Faculty of Health Sciences, Nottingham, United Kingdom;
N07: Current practices of Ultrasound for assessment of Crohn’s Disease in the UKECCO'22
Year: 2022
Authors: RadfordBSc- MSc- PGCert- PhD student, S.(1);Moran, G.(1);
(1)Nottingham NIHR Biomedical Research Centre, Inflammatory Bowel Disease, Nottingham, United Kingdom;Nottingham NIHR Biomedical Research Centre
N08: The influence of the Covid-19 epidemic on access to medical advice for children with Inflammatory Bowel Disease (IBD), based on patients from The Children's Memorial Health Institute, Warsaw (IPCZD).ECCO'22
Year: 2022
Authors: Kotkowicz Szczur, M.(1);Matuszczyk, M.(2);Kierkuś, J.(2);
(1)Instytut Pomnik Centrum Zdrowia Dziecka, Oddział Gastroenterologi- Hepatologii i Zaburzeń Karmienia, Warsaw, Poland;(2)The Children's Memorial Health Institute., Department of Gastroenterology- Hepatology- Feeding disorders and Pediatrics, Warsaw, Poland;
N09: Disease knowledge and quality of life perception in Inflammatory Bowel Disease: a randomised controlled trialECCO'22
Year: 2022
Authors: MartinatoRN PhD, M.(1);Comoretto, R.I.(2);Monaco, E.(1);Ocagli, H.(1);Gregori, D.(1);
(1)University of Padova, Department of Cardiac- Thoracic- Vascular Sciences and Public Health, Padova, Italy;(2)University of Torino, Department of Public Health and Pediatric, Torino, Italy;
N10: The impact of an educational and networking event on nurses caring for Inflammatory Bowel Disease (IBD) paediatric patients receiving biologic therapyECCO'22
Year: 2022
Authors: Gil Zaragozano, E.(1);Wiskin, A.(1);Williams, J.(2);
(1)University Hospitals Bristol and Weston NHS Foundation Trust, Paediatric Gastroenterology, Bristol, United Kingdom;(2)University of the West of England, Faculty of Health and Applied Sciences, Bristol, United Kingdom;
N11: Development of a young person clinic for 16-24-year-olds with Inflammatory Bowel Disease (IBD), using a multidisciplinary team (MDT) approach.ECCO'22
Year: 2022
Authors: Hamzawi, M.(1);Hickey, Y.(1);Brannick, S.(1);Brett Kilmurray, O.(1);Jones, F.(1);Sheridan, J.(1);Cullen, G.(1);
(1)St Vincent's University Hospital, Department of Gastroenterology, Dublin, Ireland;
N12: Systematic Review: The role of psychological stress in Inflammatory Bowel DiseaseECCO'22
Year: 2022
Authors: Black, J.(1);Sweeney, L.(1);Yuan, Y.(1);Singh, H.(2);Norton, C.(1);Czuber-Dochan, W.(1);
(1)King's College London, Florence Nightingale Faculty of Nursing- Midwifery & Palliative Care, London, United Kingdom;(2)Study Advisory Group, n/a, London, United Kingdom;
N13: Clinical service delivery implications of the Covid-19 pandemic on people with inflammatory bowel disease: a qualitative studyECCO'22
Year: 2022
Authors: Kemp, K.(1);Avery, P.(2);Bryant, R.(3);Cross, A.(4);Danter, K.(3);Kneebone, A.(5);Morris, D.(6);Walker, A.(7);Whitley, L.(8);Dibley, L.(9);
(1)Manchester Royal Infirmary, Gastroenterology, Manchester, United Kingdom;(2)St Mark's Hospital- Harrow, IBD Unit, London, United Kingdom;(3)Patient and Public Involvement Colleague, x, x, United Kingdom;(4)Gloucestershire Hospitals NHS Foundation Trust, Gastroenterology, Gloucester, United Kingdom;(5)Royal Bolton Hospital, Gastroenterology, Bolton, United Kingdom;(6)Lister Hospital, Endoscopy, Stevenage, United Kingdom;(7)South Warwickshire NHS Foundation Trust, Gastroenterology, Warwick, United Kingdom;(8)University College London Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(9)University of Greenwich, Faculty of Education- Health and Human Sciences, London, United Kingdom;
N14: Who can do it, if not me? - Identification of biopsychosocial predictors for the quality of life, satisfaction with life, and acceptance of the gastrointestinal diseaseECCO'22
Year: 2022
Authors: Rudnik, A.(1);Piotrowicz, G.(2);Piotrowicz, A.(3);Bidzan, M.(4);Rydzewska, G.(5);
(1)University of Gdansk, Institute of Psychology, Gdańsk, Poland;(2)Independent Public Health Care of the Ministry of the Internal Affairs, Department of Gastroenterology-, Gdańsk, Poland;(3)Independent Public Health Care of the Ministry of the Internal Affairs, Department of Gastroenterology, Gdańsk, Poland;(4)University of Gdańsk, Institute of Psychology, Gdańsk, Poland;(5)Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subdivision, Warsaw, Poland;